Premium
Introduction of misoprostol for the treatment of incomplete abortion beyond 12 weeks of pregnancy in Benin
Author(s) -
Adisso Sosthène,
Hounkpatin Benjamin I.B.,
Komongui Gounnou D.,
Sambieni Olivier,
Perrin René X.
Publication year - 2014
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2014.03.002
Subject(s) - misoprostol , medicine , incomplete abortion , vacuum aspiration , abortion , obstetrics , curettage , pregnancy , products of conception , gynecology , unsafe abortion , family planning , population , surgery , research methodology , genetics , environmental health , biology
Improving the care of women who have undergone a spontaneous or induced abortion is an important step in reducing abortion‐related morbidity and mortality. Both the International Federation of Gynecology and Obstetrics (FIGO) and the World Health Organization recommend the use of manual vacuum aspiration (MVA) and misoprostol rather than sharp curettage to treat incomplete abortion. MVA was introduced into the public healthcare service in Benin in 2006 and since 2008 misoprostol has been available in 3 large maternity hospitals. The present study opted to use an oral dose of 800 μg and not to limit to pregnancies of up to 12 weeks, but to include women with second trimester abortions. After 5 years, results show that around three‐quarters of the women treated with misoprostol at 13–18 weeks of pregnancy required MVA to complete uterine evacuation and approximately one‐quarter had severe bleeding, confirming that the indication of misoprostol for incomplete abortion should be limited to pregnancies of up to 12 weeks.